Filiz Çelebi1. 1. Department of Radiology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey.
Abstract
OBJECTIVE: To evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/magnetic resonance imaging (MRI) in the detection of bone metastasis in patients with breast cancer. MATERIALS AND METHODS: From August 2018 to January 2019, a total of 23 patients with pathologically confirmed invasive breast cancer underwent whole-body hybrid 18F-FDG -PET/MRI for initial staging and follow-up of their malignancies. The number of the bone metastasis was recorded for each patient. The total 18F-FDG-PET/MRI protocol was compared with PET only and the contrast enhanced fused (CE) component for the detection of bone metastasis. RESULTS: Eight (26%) of 23 patients had bone metastasis. Bone metastases were dominantly localized in the spine (63%) and pelvis (25%). In terms of the total number of detected bone metastasis, there was a statistically significant difference between 18F-FDG-PET/MRI (mean 3.57; median 0; range, 0-2) and PET only component (mean 2.87; median 0; range, 0-1) (p=0.026), but no statistically significant difference was detected between 18F-FDG-PET/MRI and whole-body CE MRI (mean 3.43; median 0; range 0-2) (p=0.083). CONCLUSION: Whole-body hybrid 18F-FDG-PET/MRI is superior to PET component only, but no statistically significant difference between hybrid 18F-FDG-PET/MRI and whole-body CE MRI is found for the detection of bone metastasis in patients with breast cancer.
OBJECTIVE: To evaluate the diagnostic performance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/magnetic resonance imaging (MRI) in the detection of bone metastasis in patients with breast cancer. MATERIALS AND METHODS: From August 2018 to January 2019, a total of 23 patients with pathologically confirmed invasive breast cancer underwent whole-body hybrid 18F-FDG -PET/MRI for initial staging and follow-up of their malignancies. The number of the bone metastasis was recorded for each patient. The total 18F-FDG-PET/MRI protocol was compared with PET only and the contrast enhanced fused (CE) component for the detection of bone metastasis. RESULTS: Eight (26%) of 23 patients had bone metastasis. Bone metastases were dominantly localized in the spine (63%) and pelvis (25%). In terms of the total number of detected bone metastasis, there was a statistically significant difference between 18F-FDG-PET/MRI (mean 3.57; median 0; range, 0-2) and PET only component (mean 2.87; median 0; range, 0-1) (p=0.026), but no statistically significant difference was detected between 18F-FDG-PET/MRI and whole-body CE MRI (mean 3.43; median 0; range 0-2) (p=0.083). CONCLUSION: Whole-body hybrid 18F-FDG-PET/MRI is superior to PET component only, but no statistically significant difference between hybrid 18F-FDG-PET/MRI and whole-body CE MRI is found for the detection of bone metastasis in patients with breast cancer.
Authors: Moaaz Soliman; Neil K Taunk; Robert E Simons; Joseph R Osborne; Michelle M Kim; Nicholas J Szerlip; Daniel E Spratt Journal: Neurosurg Focus Date: 2017-01 Impact factor: 4.047
Authors: Andreas Gutzeit; Aleksis Doert; Johannes M Froehlich; Boris P Eckhardt; Andreas Meili; Patrick Scherr; Daniel T Schmid; Nicole Graf; Constantin A von Weymarn; Edwin M M Willemse; Christoph A Binkert Journal: Skeletal Radiol Date: 2010-04 Impact factor: 2.199
Authors: Claire Tabouret-Viaud; Diomidis Botsikas; Bénédicte M A Delattre; Ismini Mainta; Gaël Amzalag; Olivier Rager; Vincent Vinh-Hung; Raymond Miralbell; Osman Ratib Journal: Semin Nucl Med Date: 2015-07 Impact factor: 4.446
Authors: Andrei Iagaru; Phillip Young; Erik Mittra; David W Dick; Robert Herfkens; Sanjiv Sam Gambhir Journal: Clin Nucl Med Date: 2013-07 Impact factor: 7.794
Authors: Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Thomas C Lauenstein; Lutz S Freudenberg; Susanne C Goehde; Stefan G Ruehm; Mathias Goyen; Silke Bosk; Jörg F Debatin; Jörg Barkhausen Journal: Eur Radiol Date: 2002-03-08 Impact factor: 5.315